RxDoctor Payments Data

Marc Simon, MD

Advanced Heart Failure and Transplant Cardiology · San Francisco, CANPI 1346215449

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $68,681 of the $114,392 with a category attached, or 60.0%. 17 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 29.5% of the total.

$114,392in general payments, 2019–2025

Across 239 payments — averaging $478.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$34K
  • Merck$31K
  • United Therapeutics Corporation$20K
  • Actelion Pharmaceuticals, Ltd$15K
  • Bayer$11K
  • Chiesi USA, Inc.$960
  • plus $3K from 11 others
$536,562in research payments, 2019–2025

Across 71 payments — averaging $7557.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$189K
  • United Therapeutics Corporation$127K
  • GSK$79K
  • E.r. Squibb & Sons, L.L.C.$61K
  • Actelion Pharmaceuticals, Ltd$35K
  • Amgen$26K
  • plus $19K from 2 others

What the payments were for

  • Consulting fees$68,68160%
  • Speaking & faculty fees$2,1002%
  • Travel & lodging$30,74627%
  • Food & beverage$12,82511%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,392 in reported general payments places this provider in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$50,705
Medicare patients
151
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag53$1,261,333
Tyvaso DpiTreprostinil42$1,253,947
OpsumitMacitentan34$425,697
AdempasRiociguat14$189,442
JardianceEmpagliflozin44$53,331
Tadalafil28$31,299
Ambrisentan12$16,619
Praluent PenAlirocumab15$7,083
Tacrolimus13$1,352
Sildenafil Citrate13$446
Spironolactone41$294
Metoprolol Succinate14$284
Rosuvastatin Calcium13$190
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$75
Losartan Potassium13$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$33,756$1,687,03087 claims
BayerAdempas$11,238$189,44214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →